RESUMEN
Abstract Background: Premature loss of deciduous teeth is the exfoliation or extraction before physiological replacement with < 50% or < 75% of the root of the substitute tooth formed or if there is > 1 mm of alveolar bone covering the permanent successor tooth organ. This study aimed to estimate the prevalence of premature tooth loss in children and identify associated factors in a health center in Acapulco, Guerrero. Methods: We conducted a cross-sectional study in which we collected information from 109 clinical records of children examined from January 2019 to August 2021. Sociodemographic data of the children and parents were collected: socioeconomic level, non-pathological personal history, and the history of premature deciduous tooth loss. Multivariate analysis to identify factors associated with premature deciduous tooth loss was performed with CIETmap statistical software. Odds ratio (OR) and 95% confidence interval (CI) were calculated to estimate the strength of the association. Results: The prevalence of premature loss of primary teeth was 40% (43/109). The leading cause was caries (84%, 36/43). The tooth organ with the highest loss occurrence was the lower right second molar (33%, 14/43). Gender was identified as an associated factor, with males having a higher risk of loss (ORa = 2.97; CI95% = 1.33-6.65). Conclusions: Our results were similar to those reported in other studies. Strategies aimed at health promotion directed at parents and children should be reinforced.
Resumen Introducción: Se considera como pérdida prematura de dientes deciduos a la exfoliación o extracción antes del recambio fisiológico con < 50% o < 75% de la raíz del diente sustituto formado, o si existe > 1 mm de hueso alveolar cubriendo al órgano dentario sucesor permanente. El objetivo de este trabajo fue estimar la prevalencia de pérdida prematura dental en niños e identificar factores asociados en un centro de salud de Acapulco, Guerrero. Métodos: Se llevó a cabo un estudio transversal en el que se recopiló información de 109 expedientes clínicos de niños atendidos de enero de 2019 a agosto de 2021. Se recolectaron datos sociodemográficos de los niños y los padres: nivel socioeconómico, antecedentes personales no patológicos y el antecedente de la pérdida prematura del diente deciduo. Se realizó un análisis multivariado para identificar factores asociados con la pérdida prematura de dientes deciduos con el software estadístico CIETmap. Se calcularon la razón de momios (OR) y el intervalo de confianza (IC) del 95% para estimar el grado de la asociación. Resultados: La prevalencia de pérdida prematura de dientes primarios fue del 40% (43/109). La principal causa fue por caries (84%, 36/43). El órgano dentario con más ocurrencia de pérdida fue el segundo molar inferior derecho (33%, 14/43). Se identificó el sexo como factor asociado, y se observó que el sexo masculino presenta mayor riesgo de pérdida (ORa = 2.97; IC95% = 1.33-6.65). Conclusiones: Nuestros resultados fueron similares a lo reportado en otros estudios. Deben reforzarse las estrategias de promoción de la salud dirigidas a los padres de familia y a sus hijos.
RESUMEN
Mycobacterium kansasii extrapulmonary infections are infrequent in immunocompetent adults. Rifampin (RIF), clarithromycin (CLR), isoniazid (INH) and ethambutol (EMB) are included in all the standard regimens against M.kansasii. We report a case of a healthy 65-year-old male farmer who presented with isolated right supraclavicular lymphadenopathy. The lymph node FNA showed acid-fast-bacilli and granulomatous inflammation. Quantiferon TB Gold test, HIV serology, and functional immunological studies were all negative or normal. He was put on a standard 4 drugs anti-tuberculous regimen that was switched to RIF + CLR+ INH after the Microbiology lab demonstrated an EMB-resistant Mycobacterium kansasii isotype I strain. The patient was cured after 12 months of therapy. This is the 6th reported case of M. kansasii extrapulmonary lymphadenitis in an immunocompetent adult and the 2nd showing EMB resistance in the world literature. Antimycobacterial regimens against M. kansasii, classically resistant to pyrazinamide (PZA) might also exclude EMB due to its increasing resistance in Europe. A 612 months therapy with at least 2 effective antimycobacterial drugs including RIF + CLR might be enough to treat extrapulmonary M. kansasii infections in immunocompetents.
RESUMEN
Marine Actinobacteria are emerging as an unexplored source for natural product discovery. Eighty-seven deep-sea coral reef invertebrates were collected during an oceanographic expedition at the submarine Avilés Canyon (Asturias, Spain) in a range of 1500 to 4700 m depth. From these, 18 cultivable bioactive Actinobacteria were isolated, mainly from corals, phylum Cnidaria, and some specimens of phyla Echinodermata, Porifera, Annelida, Arthropoda, Mollusca and Sipuncula. As determined by 16S rRNA sequencing and phylogenetic analyses, all isolates belong to the phylum Actinobacteria, mainly to the Streptomyces genus and also to Micromonospora, Pseudonocardia and Myceligenerans. Production of bioactive compounds of pharmacological interest was investigated by high-performance liquid chromatography (HPLC) and gas chromatography-mass spectrometry (GC-MS) techniques and subsequent database comparison. Results reveal that deep-sea isolated Actinobacteria display a wide repertoire of secondary metabolite production with a high chemical diversity. Most identified products (both diffusible and volatiles) are known by their contrasted antibiotic or antitumor activities. Bioassays with ethyl acetate extracts from isolates displayed strong antibiotic activities against a panel of important resistant clinical pathogens, including Gram-positive and Gram-negative bacteria, as well as fungi, all of them isolated at two main hospitals (HUCA and Cabueñes) from the same geographical region. The identity of the active extracts components of these producing Actinobacteria is currently being investigated, given its potential for the discovery of pharmaceuticals and other products of biotechnological interest.